Mangoceuticals, Inc. MGRX
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -59.07% | -37.88% | -10.27% | -36.88% | 3.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -59.07% | -37.88% | -10.27% | -36.88% | 3.00% |
| Cost of Revenue | -68.67% | -17.58% | 86.85% | -34.32% | -16.27% |
| Gross Profit | -50.83% | -53.30% | -40.70% | -38.45% | 28.80% |
| SG&A Expenses | -79.49% | -2.38% | -76.33% | 376.79% | 138.92% |
| Depreciation & Amortization | -- | -- | 55.59% | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -79.33% | -2.60% | -36.44% | 364.06% | 132.59% |
| Operating Income | 79.99% | 1.38% | 37.59% | -399.61% | -142.53% |
| Income Before Tax | 75.76% | 29.68% | -42.12% | -281.00% | -126.48% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 75.76% | 29.68% | -42.12% | -281.00% | -126.48% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -100.00% | -200.00% | 20.00% | -100.00% |
| Net Income | 75.76% | 29.68% | -42.15% | -281.06% | -126.51% |
| EBIT | 79.99% | 1.38% | 37.59% | -399.61% | -142.53% |
| EBITDA | 82.94% | -2.91% | 37.46% | -398.06% | -106.39% |
| EPS Basic | 83.60% | 79.93% | 70.96% | 39.70% | 58.38% |
| Normalized Basic EPS | 85.54% | 80.39% | 85.69% | 33.41% | 61.43% |
| EPS Diluted | 83.60% | 79.93% | 70.96% | 39.70% | 58.38% |
| Normalized Diluted EPS | 85.54% | 80.39% | 85.69% | 33.41% | 61.43% |
| Average Basic Shares Outstanding | 71.48% | 258.83% | 441.42% | 472.27% | 473.76% |
| Average Diluted Shares Outstanding | 71.48% | 258.83% | 441.42% | 472.27% | 473.76% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |